The addition of sildenafil to nintedanib provides no improvements in health-related quality of life (HRQoL) in patients with idiopathic pulmonary fibrosis (IPF), according to results of the INSTAGE study presented at the 28th European Respiratory Society International Congress 2018 (ERS 2018).
Digital mindfulness is an acceptable nonpharmacological intervention that can be integrated with existing treatment for patients with asthma to improve quality of life, according to a study from the UK reported at the recent European Respiratory Society (ERS) International Congress 2018.
The anti–interleukin-5 (anti–IL-5) agent reslizumab significantly improves disease control and lung function and reduces the need for oral steroid maintenance therapy in patients with severe eosinophilic asthma, results of a real-life study have shown.
Interstitial lung abnormalities (ILA), a common finding in low-dose chest CT, are associated with a 5.5-fold increase in risk of lung cancer over long-term follow-up, according to a study reported at the European Respiratory Society (ERS) International Congress 2018.
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Despite a 90-percent cure rate after first treatment for children with acute lymphoblastic leukaemia (ALL), approximately 10–15 percent of patients with paediatric ALL will experience relapse. [Expert Rev Anticancer Ther 2017;17:725-736] A recent webinar on the current landscape of ALL highlighted the potential of immunotherapy for paediatric patients with relapsed or refractory ALL, thus providing hope for this high-risk patient group.